PT  - JOURNAL ARTICLE
AU  - Taylor, Rachel A.
AU  - McCarthy, Catherine
AU  - Patel, Virag
AU  - Moir, Ruth
AU  - Kelly, Louise A
AU  - Snary, Emma L
TI  - The risk of introducing SARS-CoV-2 to the UK via international travel in August 2020
AID  - 10.1101/2020.09.09.20190454
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.09.09.20190454
4099  - http://medrxiv.org/content/early/2020/09/09/2020.09.09.20190454.short
4100  - http://medrxiv.org/content/early/2020/09/09/2020.09.09.20190454.full
AB  - International travel poses substantial risks for continued introduction of SARS-CoV-2. As of the 17th August 2020, travellers from 12 of the top 25 countries flying into the UK are required to self-isolate for 14 days. We estimate that 895 (CI: 834–958) infectious travellers arrive in a single week, of which 87% (779, CI: 722–837) originate from countries on the UK quarantine list. We compare alternative measures to the 14 day self-isolation (78.0% effective CI: 74.4–81.6) which could be more feasible long-term. A single RT-PCR taken upon arrival at the airport is 39.6% (CI: 35.2–43.7) effective, or equivalently, it would only detect 2 in 5 infectious passengers. Alternatively, testing four days after arrival is 64.3% (CI: 60.0–68.3) effective whereas a test at the airport plus additional test four days later is 68.9% (CI: 64.9–73.0) effective. Rapidly implementing control measures for travellers from risky countries is vital to protect public health; this methodology can be quickly updated to assess the impact of any further changes to international travel policy or disease occurrence.Competing Interest StatementThe authors have declared no competing interest.Funding StatementPublic Health England (PHE) commissioned and funded this work as well as providing data on worldwide cases, deaths and tests for COVID-19. They did not have any role in the model design, analysis or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicableAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNot applicable